VivoSim Labs, Inc. (NASDAQ:VIVS) Sees Large Decrease in Short Interest

VivoSim Labs, Inc. (NASDAQ:VIVS) was the target of a significant decrease in short interest during the month of February. As of February 13th, there was short interest totaling 87,870 shares, a decrease of 88.7% from the January 29th total of 774,911 shares. Approximately 3.5% of the company’s stock are sold short. Based on an average daily trading volume, of 394,842 shares, the days-to-cover ratio is currently 0.2 days. Based on an average daily trading volume, of 394,842 shares, the days-to-cover ratio is currently 0.2 days. Approximately 3.5% of the company’s stock are sold short.

Institutional Investors Weigh In On VivoSim Labs

An institutional investor recently bought a new position in VivoSim Labs stock. Two Sigma Investments LP acquired a new position in VivoSim Labs, Inc. (NASDAQ:VIVS) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 23,192 shares of the company’s stock, valued at approximately $68,000. Two Sigma Investments LP owned 0.89% of VivoSim Labs as of its most recent SEC filing. 8.23% of the stock is currently owned by institutional investors.

VivoSim Labs Trading Up 5.7%

VivoSim Labs stock traded up $0.11 during midday trading on Wednesday, reaching $2.05. 105,872 shares of the stock traded hands, compared to its average volume of 4,915,803. VivoSim Labs has a fifty-two week low of $1.41 and a fifty-two week high of $18.60. The firm has a market cap of $5.35 million, a price-to-earnings ratio of -0.97 and a beta of 1.21. The firm has a fifty day moving average price of $2.03 and a two-hundred day moving average price of $2.37.

VivoSim Labs (NASDAQ:VIVS) last issued its quarterly earnings data on Wednesday, February 11th. The company reported ($1.03) earnings per share (EPS) for the quarter. VivoSim Labs had a negative return on equity of 15.51% and a negative net margin of 861.27%.The business had revenue of $0.03 million for the quarter.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of VivoSim Labs in a research note on Wednesday, January 21st. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, VivoSim Labs has an average rating of “Sell”.

About VivoSim Labs

VivoSim Labs, Inc (NASDAQ: VIVS) is a biotechnology company specializing in the development and commercialization of advanced 3D human tissue models for preclinical drug testing and disease modeling. The company’s proprietary organoid platforms and cell-based assays are designed to replicate human physiological environments, enabling more predictive evaluation of drug efficacy, safety, and toxicity before clinical trials. By integrating cutting-edge bioengineering and microfluidics technologies, VivoSim Labs seeks to bridge the gap between traditional cell culture methods and human clinical outcomes.

The company’s product portfolio includes 3D bioprinted tissues, organ-on-a-chip systems, and disease-specific models targeting key therapeutic areas such as oncology, cardiology, and hepatology.